anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a multicenter, observational cohort trial in the real-world clinical setting recruiting MG patients from Neurology Departments of 6 hospitals in different regions of China. Clinical manifestations, laboratory test results, chest imaging and history of thymectomy are recorded. Patients will be classified by clinical manifestation as well as antibody status, and treatment regimens are determined according to the physician's judgment and preferences of the patients. Patients are followed up prospectively on regular to assess the outcomes of treatments and monitor any side effects. Peripheral blood samples are collected annually. Patients' clinical records are uploaded to an online database. The investigators plan to recruit a final sample of 2000 patients for analysis.
Stimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
In this randomized controlled trial, 96 eyes of females with dry eye will be recruited through random sampling. Dry eye assessments will be done including TBUT, Schirmer test 1, and OSDI questionnaire. 96 eyes will be divided into 3 groups (32 eyes each) and will be provided intervention which is Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. , Dextran 0.1%Hypromellose 0.3%, and placebo(normal saline) through randomization by an unmasked investigator. Changes in central and peripheral corneal thickness will be evaluated by corneal topography. Patients will be evaluated at baseline, after 15 days, after 1 month, and re-evaluated after 1 month of cessation of treatment.
The invention provides a dronedarone hydrochloride pharmaceutical composition which is suitable for the sublingual administration, can quickly run, and can greatly improve the bioavailability and the curative effect. The pharmaceutical composition consists of 5-65 parts of dronedarone hydrochloride, 1-10 parts of a disintegrating agent, 10-80 parts of filler, 0.5-3 parts of antacid, 0-5 parts of corrigent, 1-10 parts of an adhesive and 0.3-2 parts of a lubricating agent. The invention further provides a preparation method suitable for the industrial production. The dronedarone hydrochloride pharmaceutical composition provided by the invention is directly absorbed by the sublingual mucosa, and the first-pass effect of oral medicaments can be avoided, and the gastrointestinal digestion, acidolysis and the like can be avoided, so that the bioavailability can be greatly improved. The epithelium of the sublingual mucosa is not cornified, so that the dronedarone hydrochloride pharmaceutical composition is large in superficial area, and high in infiltration capacity. The medicament can be quickly absorbed after being administrated, so that the dronedarone hydrochloride pharmaceutical composition is quick to run, and convenient to use; and compared with the other administrated preparations, the dronedarone hydrochloride pharmaceutical composition is convenient to administrate, and good in patient compliance.
Subjects will be referred to the PI by the Yale Liver Center. If interested in participating, they will be contacted by a research assistant for an initial phone screening. If the subject passes the screening, an appointment will be made for a MRS and fMRI at the Yale Magnetic Resonance Research Center (MRRC). Subjects will be asked to abstain from their HE medication (e.g. lactulose and/or rifaximin) for 12 hours prior to their appointment. At their appointment for MRS/fMRI, they will receive two IVs, one for medication infusion and another for periodic blood draws during the MRS. Subjects will be blindly randomized to one of two groups: A or B. Group A will receive flumazenil (Romazicon) and Group B will receive placebo (saline). One week post-infusion, patients will crossover groups; those originally in Group A will crossover to Group B and those originally in Group B will crossover to Group A. Once ready, a priming dose bolus of 0.4 mg of either flumazenil or placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of flumazenil or placebo mixed with saline will be administered to the patient at a rate of 0.1 mg flumazenil or placebo per minute for a total of 7 doses during the scan. A baseline pharmacokinetics (PK) sample will be drawn, processed and frozen and the intravenous line used to draw the sample will remain in patient until all samples have been drawn. Seven additional PK samples (2-4 mL each) collected during and after the scan will be used to evaluate the level of flumazenil circulating throughout the bloodstream during the course of the infusion and during the washout period.

Following the MRS and fMRI, subjects will undergo a 40-minute neuropsychologic battery. Other testing procedures include liver function and drug testing. All procedures will repeat one week later with placebo or flumazenil infusion (based on the group to which he/she has been randomized). A follow-up phone call to assess for adverse events will take place in week 3.
NEW MATERIAL:The compound of formula I (R is diterpenyl). EXAMPLE:Acetaldehyde phytylethyl acetal of formula II. USE:A component of perfumery composition. It is an almost odorless and colorless clear liquid having high safety. It is useful as a retainer to control the volatilization of the perfume component, and keep the original perfume stably for a long period without loss; and sometimes, it is used for suppressing the chemical changes such as polymerization, condensation, oxidation, decomposition, etc. of the perfume component caused by light, heat, moisture, etc., and for diluting or dissolving a highly viscous, pasty or solid perfume component. PROCESS:The compound of formula I can be prepared by reacting the diterpene alcohol of formula III (R is phytyl, isophytyl or geranyl-linalyl) with ethyl vinyl ether of formula IV in a state acdified with phosphoric acid, etc., at 10-60 deg.C for 1-3hr.
Participants meeting study inclusion will then be scheduled for 4 fMRI sessions to assess and manipulate the ability to self-stimulate VTA activation. Each session will contain the same tasks and instructions. The experimental imaging task sessions will be done 24-72 hours apart and will consist of two types of runs: Test Runs (one pre-test and post-test each) and three Training Runs. Participants will be instructed to achieve heightened state of motivation using personally relevant thoughts and imagery.
Patient outcomes after rotator cuff repair vary greatly and depend on the size of the tear itself. Researchers have identified a number of devices that can be used to reinforce the surgical repair and enhance the structure and function of both the muscles and tendons (Jo et al., 2011; Randelli, Arrigoni, Ragone, MEng, Aliprandi, Cabitza, 2011; Proctor, 2014). Reinforcement patches have been used to help improve surgical outcomes, including: allograft rotator cuff, human cadaveric skin, pig and bovine skin, equine pericardium, and porcine intestinal submucosa (Randelli, Arrigoni, Ragone, MEng, Aliprandi, Cabitza, 2011). Although synthetic patches have also shown some effectiveness, these patches do not provide biologic augmentation of the tendon repair (Jo et al., 2011).

Additionally, there has been some research examining the effectiveness of using platelet-rich plasma therapy to help repair both rotator cuff tendinopathy and tears. Platelets play an important role in the healing process and it has been theorized that exposing inflamed or healing tissue to higher densities of platelets can contribute to less pain, better range of motion (ROM), and overall healing (Pandey et al., 2016). The consensus on this type of therapy has shown inconclusive results, however. For example, research by Jo et al. (2011) found no significant change in clinical recovery in respect to pain or ROM compared to a control group. Alternatively, Pandey et al. (2016) found significant improvements in both pain and ROM scores as well as decreased re-tear rates in the plasma-rich protein treatment group. These and other similar studies utilized different methodologies for patient populations (tendinopathy versus full tears, etc.), treatment timing, formulation of platelet-rich plasma or whole blood fibrin clot, and time of follow-up. Further research is needed to identify what treatments, if any, in the field of platelet-rich plasma are most beneficial for patients with rotator cuff tears. Recent research has demonstrated that whole blood fibrin clots concentrate 98% of available platelets and release growth factors including vascular endothelial growth factor over two weeks (Siegel, Clevenger, Proctor, Clegg, \& Proctor, 2017). However, clinical evidence indicating the effect of whole blood fibrin clots on the healing of repaired torn rotator cuffs is lacking (Jo et al., 2011). The goal of this study is to assess whether undergoing surgical repair of the rotator cuff with the additional intervention of whole blood fibrin clot will improve rotator cuff vascularization at the bone-tendon interface repair site and patient outcomes compared to those who do not receive the whole blood fibrin clot intervention.
The present invention relates to a method of manufacturing and using heat shock proteins containing a step of initiating a coagulative necrotic process in a tissue. In particular, a method of manufacturing and using heat shock proteins comprises the steps of heating a tissue to initiate the coagulative necrotic process for a period of time, cooling the tissue, incubating the tissue in an appropriate growth medium, and collecting the supernatant from the tissue. In a preferred embodiment, the coagulative necrotic process is initiated by heating the tissue to 60°; or more. The tissue is then cooled to room temperature before incubating the tissue in growth media for 48 hours or less. Heat shock proteins produced in accordance with this method may be complexed to peptides or antigens to produce autologous vaccines in the prevention and treatment of various diseases. Furthermore, heat shock proteins may be used in diagnostic assays for various autoimmune and inflammatory diseases. Heat shock proteins produced in accordance with this method may also be used to quantify antibody levels that serve as disease markers.
PURPOSE:To obtain a perfume containing conchiolin as an active ingredient, relieving irritation to skin and having good scent and fragrance-retaining property. CONSTITUTION:This perfume contains conchiolin being a sort of hard protein contained in shell and pearls and contained in relatively larger amounts in Japanese pearl oyster, fresh-water mussel, etc., as an active ingredient. Conchiolin is obtained by pulverizing the shell, removing calcium content with diluted hydrochloric acid, etc., from the resultant powder, collecting insoluble matter by a solid-liquid separation method such as centrifugal separation or filtration decantation, adding purified water to the insoluble matter, collecting the insoluble matter by stirring, centrifugal separation, filtration, etc. and repeatedly carrying out above steps. Further, hydrolyzate of the conchiolin obtained by adding 2-10wt.% of an aqueous solution of hydrochloric acid to this conchiolin, hydrolyzing conchiolin at 50-110 deg.C for 5hr to 5 day may be utilized as a active ingredient for the perfume. 0.1-20wt.% of water may be added thereto to improve solubility, etc., of conchiolin. A polyhydric alcohol (e.g. glycerin) may be added to the perfume to control fragrance-retaining property of the perfume. The conchiolin is useful for perfumes including eau de Cologne, eau de toilette, eau de perfume or a compound perfume.
The home-based exercise group will be asked to exercise 3 to 5 times per week (≥ 150 minutes of aerobic exercises (i.e. walking, cycling, or treadmill) of at least moderate intensity) and to also complete resistance training (resistance bands or free weights) at least twice weekly over a 12-week period supervised by an exercise professional. The resistance training will be personalized, aiming for 6 to 10 exercises targeting the major muscle groups, progressing to 3 sets of 8 to 12 repetitions. Exercise prescriptions will be developed and monitored by an exercise professional with weekly follow-up meetings and supported with a web application (Physiotec) that allows customizable exercise prescriptions, tracking of exercise completion, and video tutorials. Participants will receive one counselling session on healthy eating and physical activity at the start of the study along with an exercise manual.
The present invention is to provide a metal oxide organopolysiloxane hybrid powder, wherein a silicon atom of organopolysiloxane is bonded by covalent bond with a metal atom through an oxygen atom and complicated homogeneously. Titanium and/or zirconium is desirably used as the above mentioned metal atom. Especially, a porous titanium oxide organopolysiloxane hybrid powder whose specific surface area is larger than 50 m 2 /g is desirably used. Said hybrid powder can be produced by generating sol by hydrolysis of metal alkoxide, adding reactive organopolysiloxane to said sol to generate hybrid sol solution, then precipitating it. The method to produce titanium oxide.silica composite by the heat treatment of porous titanium oxide.organopolysiloxane hybrid powder can be also mentioned. By making hybrid, the optical properties of metal oxide powder can be controlled and dispersing ability, dispersing stability, water repellency and hard feeling can be improved. By blending this hybrid powder in cosmetic composition, the cosmetic composition which is excellent at feeling at the actual use, natural makeup, long lasting and ultra violet ray screening effect can be obtained.
<P>PROBLEM TO BE SOLVED: To provide methods and compositions for reducing the incidence of necrotizing enterocolitis.  <P>SOLUTION: An enteral container and such enteral compositions including long-chain polyunsaturated fatty acids (PUFAs), for example, arachidonic acid (AA) and docosahexaenoic acid (DHA) essentially free of cholesterol can reduce the incidence of necrotizing enterocolitis by administering compositions which provide n-6 and n-3 long-chain PUFAs, phospholipids and/or choline. Compositions from egg yolk lipids are presently preferred as they contain n-6 and n-3 long-chain PUFAs and are predominantly in a phosphtidylcholine form. This is believed to provide a synergistic effect. The process of producing such a composition that improves organoleptic and imparts stability properties is also disclosed.  <P>COPYRIGHT: (C)2011,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To stably eject a mixture solution of a first agent and a second agent of a two-pack type hair dyeing or bleaching composition in the form of fine foam by using a squeeze container.  <P>SOLUTION: A method for dyeing or bleaching hair comprises ejecting the mixture solution A3 of the first agent A1 and the second agent A2 of the two-pack type hair dyeing or bleaching composition in the form of foam from the squeeze container 6 and applying the mixture solution to the hair. A squeeze container comprising a container body 4 and a squeeze foamer 5 is used as the squeeze container 6. At least either of the first agent A1 and the second agent A2 contains a foaming agent and the first agent A1 and the second agent A2 providing a viscosity (25°C) of 1-100 mPa s to the mixture solution are used. The first agent A1 is mixed with the second agent A2 in the container body 4 in such a way that no bubbling occurs and the squeeze container 6 is squeezed in a standing state in order to inhibit the mixture solution A3 from reaching to an air introduction passage 12 of the squeeze foamer 5.  <P>COPYRIGHT: (C)2009,JPO&INPIT
ETHNOPHARMACOLOGICAL RELEVANCE: Gentiana kurroo Royle is a medicinal plant mentioned as Traymana in Ayurveda. In the folklore, it is used to cure fever, stomach ache, skin diseases and liver disorders. However, limited reports are available on the therapeutic potential of Gentiana kurroo Royle against alcohol-induced liver damage.
AIM OF THE STUDY: To assess the effectiveness of the hydroethanolic extract of Gentiana kurroo Royle rhizome (GKRE) against alcohol-induced liver injury and explore the mechanism of action.
MATERIALS AND METHODS: GKRE was characterized using UHPLC-QTOF-MS/MS. The binding affinity of the identified compound was studied in silico. In vitro studies were performed in the Huh-7 cell line. An acute oral toxicity study (2 g/kg BW) of GKRE was done in rats following OECD 420 guidelines. In the efficacy study, rats were treated with 50% ethanol (5 mL/kg BW, orally) for 4 weeks, followed by a single intraperitoneal dose of CCl4 (30%; 1 mL/kg BW) to induce liver injury. After 4th week, the rats were treated with GKRE at 100, 200 and 400 mg/kg BW doses for the next fifteen days. The biochemical and antioxidant parameters were analyzed using commercial kits and a biochemistry analyzer. Histopathology, gene and protein expressions were studied using qRT PCR and western blotting.
RESULTS: Thirteen compounds were detected in GKRE. Few compounds showed a strong interaction with the fibrotic and inflammatory proteins in silico. GKRE reduced (p < 0.05) the ethanol-induced ROS production and inflammation in Huh-7 cells. The acute oral toxicity study revealed no adverse effect of GKRE in rats at 2 g/kg BW. GKRE improved (p < 0.05) the body and liver weights in ethanol-treated rats. GKRE improved (p < 0.05) the mRNA levels of ADH, SREBP1c and mitochondrial biogenesis genes in the liver tissues. GKRE also improved (p < 0.05) the liver damage markers, lipid peroxidation and levels of antioxidant enzymes in the liver. A reduced severity (p < 0.05) of pathological changes, fibrotic tissue deposition and caspase 3/7 activity were observed in the liver tissues of GKRE-treated rats. Further, GKRE downregulated (p < 0.05) the expression of fibrotic (TGFβ, αSMA and SMADs) and inflammatory markers (TNFα, IL6, IL1β and NFκB) in the liver.
CONCLUSION: GKRE showed efficacy against alcohol-induced liver damage by inhibiting oxidative stress, apoptosis, inflammation and fibrogenesis in the liver.
The present invention pertains to a novel cell based tumor vaccine platform. The invention provides a method for modifying antigen presenting cells (APCs) to present both MHC class I and/or MHC class II peptides in context of improved peptide presentation protein complexes in order to increase activation of a patient's immune response. In this invention, an MHC II mRNA dendritic cell based vaccine platform was developed to activate CD4 +  T cells in patients and to enhance the anti-tumor response. The invariant chain (Ii) was modified and the semi-peptide CLIP was replaced with an MHC II binding peptide sequences of tumor associated antigens. These chimeric MHC II constructs are presented by APCs and induce proliferation of tumor specific CD4 +  T cells. The invention provides the constructs, proteins, nucleic acids, recombinant cells, as well as medical applications of these products.
Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
BACKGROUND: Health care costs attributed to COPD have been estimated at $4.7 trillion globally in the next 30 years. With the global burden of COPD rising, identification of interventions that might lead to health care cost savings is an imperative. Although many studies report the effect of COPD self-management interventions on subject outcomes and health care utilization, few data describe their effect on health care costs.
METHODS: Using data linkage and established case-costing methods with provincial Canadian health databases, we established public health care costs (acute and community) for 12 months following randomization for the 462 participants enrolled in our randomized controlled trial of the Program of Integrated Care for Patients with COPD and Multiple Comorbidities.
RESULTS: Total median (interquartile range) in-hospital costs in the 12 months follow-up for all (intervention and control) 462 trial participants were CAD $4,769 ($417-16,834) (equivalent to US $3,566 [$312-12,588]). Total costs incurred in the community were higher at CAD $8,011 ($4,749-13,831) (equivalent to US $5,990 [$3,551-10,342]). Controlling for sex, income quintile, Johns Hopkins Aggregated Diagnosis Groups score, and living in an urban locality, we found lower community health care costs but no differences in acute care costs for participants receiving our multicomponent COPD exacerbation prevention management intervention compared to usual care.
CONCLUSIONS: Controlling for important confounders, we found lower public community health care costs but no difference in acute health care costs with our multicomponent COPD exacerbation prevention management intervention compared to usual care. Community health care costs were almost double those incurred compared to acute health care costs. Given this finding, although most COPD exacerbation management interventions generally focus on reducing the use of acute care, interventions that enable health care cost savings in the community require further exploration.
To investigate the associated risk factors affecting necrosis of the nasal septal mucosal flap (NSF) after salvage surgery for recurrent nasopharyngeal carcinoma (NPC). A retrospective analysis was conducted on patients with recurrent NPC who underwent endoscopic salvage surgery and NSF repair. Factors analyzed included second-course radiotherapy history, recurrence T stage, recurrence time, and postoperative packing time. Logistic regression identified independent risk factors. Second-course radiotherapy, advanced T stage recurrence, longer recurrence time, and shorter postoperative packing time were identified as independent risk factors for NSF necrosis. Patients with second-course radiotherapy had an 8.338 times higher risk of flap necrosis. Advanced T stage and longer recurrence times were also associated with increased risk. Nasal packing for less than 5 days presented a higher risk of flap necrosis compared to packing for 5 days or more. The predictive model demonstrated good predictive ability. The second-course radiotherapy history, the recurrence T stage, the recurrence time, and the postoperative packing time are independent risk factors for necrosis of the nasal septal mucosal flap after salvage surgery for recurrent nasopharyngeal carcinoma.
36 subjects with a history of AUD within the past six months will be recruited for this study. Subjects will be randomized into three groups. Group 1 receives an active heating device and placebo c-tactile fiber stimulation. Group 2 active c tactile fiber stimulation and placebo heating device. Group 3 receives active c tactile fiber stimulation and an active heating device. All subjects will have baseline labs drawn, then undergo 10 minutes of experimental stimulation according to group number 1,2 or 3,After 10 minutes, subjects will be given a validated experimental stressor that takes approximately 15 minutes. During this time, subjects will also receive the experimental stimulation per their experimental group After the experimental stress is concluded, stimulation will continue for an additional 5 minutes. Oxytocin and cortisol via salivary samples will be collected throughout and at the conclusion of the trial. Subjects will be followed for one hour post trial. Both laboratory testing and assessment measures will be repeated at 30 and 60 minutes post experimental treatment. Assessment measures include the VAS-A, the PROMIS anxiety short form, and the desires for alcohol questionnaire. The active placebo is thermal stimulation at 37°C over the trapezius using the same number of heating pods. Placebo CT stimulation will occur by placing the von Frey filaments, which provide two standard deviations less than the optimal pressure. Subjects will not be informed about which group they were randomized into.